NMR fragment screening: tackling protein-protein interaction targets

Markus Schade1, Hartmut Oschkinat

  • 1Combinature Biopharm AG, 13125 Berlin, Germany. Schade@Combinature.com

Current Opinion in Drug Discovery & Development
|May 17, 2005
PubMed